BRCA1 and breast cancer: More recently, trabectedin, a marine-derived tetrahydroisoquinoline currently produced by chemical synthesis and approved for treating soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer, was evaluated in BRCA1/2 carriers with advanced breast cancer.